| Case Name | Drug | Patent No(s). | Publicly Available Terms |
|---|---|---|---|
|
AstraZeneca Pharma. LP v. Accord Healthcare, 08-4804, 09-619 (D.N.J.) |
Seroquel XR®(quetiapine fumarate) |
5,948,437 |
Accord agreed not to sell generic Seroquel XR®until November 2016 ‘437 patent does not expire until 2017 |
|
Pfizer Inc. v. Actavis Group HF, 10-675 (D. Del.) |
Lipitor®(atorvastatin calcium) |
5,969,156 5,686,104 6,126,971 |
N/A |
|
AstraZeneca AB v. SunPharmaGlobalFZE, 10-1017 (D.N.J.) |
Nexium®I.V. (esomeprazole sodium) |
5,877,192 6,143,771 |
Sun Pharma agreed not to sell its generic drug until Jan. 2, 2014, without authorization |
|
Abbott Labs. v. Impax Labs. Inc., 10-1322 (D.N.J.) |
Trilipix®(fenofibric acid) |
7,259,186 |
Impax may launch generic product on Jan. 1, 2014, or as early as July 15, 2013, under certain undisclosed conditions ‘186 patent does not expire until 2025 |
|
Bristol-Myers Squibb Co. v. TevaPharma.USAInc., 09-919 (D. Del.) |
Reyatax®(atazanavir sulfate) |
5,849,911 6,087,383 |
Teva may launch generic product in July 2017, or earlier, under certain undisclosed conditions The ‘911 patent expires in June 2017 and the ‘383 patent expires in Dec. 2018 |
|
Pfizer Inc. v. AurobindoPharma. Ltd., 11-569 (D. Del.) |
Lipitor®(atorvastatin calcium) |
5,969,156 |
N/A |
|
Bayer Schering Pharma AG v. TevaPharma.USAInc., 09-480 (D. Del.) |
Levitra®(vardenafil HCl) |
6,362,178 7,696,206 |
N/A |
|
Vivelle Ventures LLC (Novartis) v. Mylan Tech. Inc., 11-1187 (S.D.N.Y.) Vivelle Ventures LLC (Novartis) v. Mylan Tech. Inc., 11-50 (D. Vt.) |
Vivelle Dot®(estradiol transdermal system) |
5,656,286 6,024,976 |
Mylan to receive a patent license to begin selling its generic product in Dec. 2013, subject to approval by USDOJ and FTC |
|
Valeant International (Barbados) SRL v. Par Pharma.Cos.Inc., 10-7310 (S.D.N.Y.) |
Aplenzin®(buproprion HBr extended release tablets) |
7,569,610 7,572,935 7,649,019 7,553,992 7,671,094 7,241,805 7,645,802 7,622,407 7,645,901 |
N/A |
|
Teva Women’s Health Inc. V. Lupin Ltd., 10-0080 (D.N.J.) |
LoSeasonique™ (ethinyl estradiol/levonorgestrel) |
7,615,545 |
Watson may launch generic product on 12/14/2011 |
|
Pfizer Inc. v. SandozInc., 09-0742 (D. Del.) |
Caduet®(amlodipine besylate/atorvastatin calcium) |
6,455,574 5,969,156 6,126,971 5,686,104 |
N/A |
|
Sanofi-Aventis v. SunPharma.Indus.Ltd., 08-6286 (S.D.N.Y.) |
Plavix®(clopidogrel bisulfate) |
6,429,210 |
N/A |
